INARI MEDICAL (NASDAQ: NARI): Kaplan Fox & Kilsheimer LLP Continues its Investigation of Inari Medical following Inari Medicals Disclosure of a DOJ Investigation related to Anti-Kickback laws

March 20, 2024 at 09:31 AM EDT

NEW YORK, NY - (NewMediaWire) - March 20, 2024 - Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Inari Medical, Inc. (“Inari Medical” or the “Company”) (NASDAQ: NARI). Click Here to Join Investigation.

If you acquired Inari Medical shares and would like to discuss our investigation, please click here or contact us by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

On February 28, 2024, after the market close, Inari Medical announced fourth quarter and full-year 2023 financial results and disclosed receipt of a civil investigative demand in December 2023 from the U.S. Department of Justice (“DOJ”) “requesting information primarily related to meals and consulting service payments provided to healthcare professionals.” In the Company’s Annual Report filed the next day with the SEC, Inari Medical indicated that that the DOJ request was in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.

Following this news, Inari Medical stock fell $12.14 per share, or 20.8%, to close at $46.12 per share on February 29, 2024.

WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

If you have any questions about this investigation, please contact:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
E-mail: pmayer@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com